The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.

The estrogen (ER) or progesterone receptors (PR) is positively associated with better clinical outcomes in ovarian cancer. Whether metastasis or recurrence of ovarian cancer is correlated with this association has not been investigated. Data on 894 women with epithelial ovarian cancer were collected and the association between ER or PR positivity and peritoneal or lymph node metastases or recurrence was analysed. ER or PR positivity was higher in high-grade, low-grade serous and endometrioid carcinoma, but lower in mucinous and clear-cell carcinoma. Significantly higher ER or PR positivity was seen in endometrioid carcinoma or high-grade serous carcinoma with peritoneal metastases, respectively, but not other subtypes. In addition, there was no significant difference in ER or PR positivity between cases with and without lymph node metastasis in these five subtypes. In recurrent high-grade serous carcinoma with peritoneal metastases (n = 103), the positivity of ER or PR was 86% and 55% respectively. Our data demonstrate that the association between ER or PR positivity and peritoneal metastases was only seen in endometrioid or high grade serous carcinoma, respectively. There was no association of ER or PR positivity and lymph node metastases. The majority of recurrent high-grade serous carcinoma with peritoneal metastases (86%) were ER positive.